Xeris Biopharma Holdings (XERS) Inventory (2020 - 2026)

Xeris Biopharma Holdings has reported Inventory for 7 years, with the latest figure at $74.2 million in Q1 2026.

• For the quarter ending Q1 2026, Inventory rose 40.89% year-over-year to $74.2 million; the trailing twelve-month figure through Mar 2026 stood at $74.2 million (up 40.89% YoY), and the FY2025 full-year result was $68.7 million, up 42.55% from the prior year.
• Inventory for Q1 2026 stood at $74.2 million, up from $68.7 million in the prior quarter.
• The five-year high for Inventory was $74.2 million in Q1 2026, with the low at $16.9 million in Q1 2022.
• Historically, Inventory has averaged $42.9 million across 5 years, with a median of $40.9 million in 2024.
• Annual changes were most pronounced in 2023 — Inventory soared 104.27% — and 2024, when it increased 17.62%.
• Xeris Biopharma Holdings' Inventory stood at $24.7 million in 2022, then soared by 57.02% to $38.8 million in 2023, then rose by 24.04% to $48.2 million in 2024, then soared by 42.55% to $68.7 million in 2025, then rose by 8.1% to $74.2 million in 2026.
• The last three Inventory figures came in at $74.2 million (Q1 2026), $68.7 million (Q4 2025), and $67.5 million (Q3 2025), per Business Quant data.